Last reviewed · How we verify
Meloxicam and Glucosamine
Meloxicam reduces inflammation and pain by inhibiting cyclooxygenase enzymes, while glucosamine supports cartilage structure and may reduce joint degradation.
Meloxicam reduces inflammation and pain by inhibiting cyclooxygenase enzymes, while glucosamine supports cartilage structure and may reduce joint degradation. Used for Osteoarthritis pain and inflammation.
At a glance
| Generic name | Meloxicam and Glucosamine |
|---|---|
| Also known as | Association Anti-inflamatory/Anti-rheumatic |
| Sponsor | Zodiac Produtos Farmaceuticos S.A. |
| Drug class | NSAID + nutraceutical combination |
| Target | COX-2 (meloxicam); cartilage matrix precursor (glucosamine) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Orthopedics |
| Phase | Phase 3 |
Mechanism of action
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, reducing prostaglandin synthesis and thereby decreasing inflammation and pain. Glucosamine is an aminomonosaccharide that serves as a precursor for glycosaminoglycan synthesis in cartilage, potentially slowing cartilage breakdown and supporting joint structure. Together, this combination addresses both acute inflammatory symptoms and underlying cartilage health in osteoarthritis.
Approved indications
- Osteoarthritis pain and inflammation
Common side effects
- Gastrointestinal upset
- Dyspepsia
- Abdominal pain
- Nausea
- Headache
Key clinical trials
- A Parallel-group Active Comparator, Double-blind, Multicenter, Randomized, Double-blind, Phase III Clinical Study (PHASE3)
- Study of Association of Anti-inflammatory and Anti-rheumatic (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meloxicam and Glucosamine CI brief — competitive landscape report
- Meloxicam and Glucosamine updates RSS · CI watch RSS
- Zodiac Produtos Farmaceuticos S.A. portfolio CI